PVLA stock news
This page provides real-time market news, earnings updates, and company announcements related to Palvella Therapeutics, Inc. (PVLA).
All content is aggregated from trusted financial media and market data sources to help investors stay informed about key market movements and corporate developments.
Last updated as of 2026-04-11 01:23 EST
Wayfair receives an upgrade, Instacart begins coverage: Leading analyst recommendations from Wall Street
101 finance2026-01-07 14:51:28
Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN 3.9% Rapamycin Anhydrous Gel (QTORIN rapamycin) in Microcystic Lymphatic Malformations
Finviz2026-02-23 22:03:56
Retiring with $7 Million: A Business Owner's Guide to Spending Your Nest Egg
101 finance2026-02-25 07:48:37
Palvella Therapeutics Announces Pricing of Upsized Public Offering
Finviz2026-02-26 01:00:50
Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
Finviz2026-03-02 12:33:44
Palvella Therapeutics Announces Issuance of European Patent Covering Anhydrous Compositions of Rapamycin
Finviz2026-03-16 11:33:05
Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services
Finviz2026-03-23 11:33:56
Palvella Therapeutics to Host Full Year 2025 Financial Results Conference Call and Provide a Corporate Update on March 31, 2026
Finviz2026-03-24 11:33:39
Palvella Therapeutics Highlights Continued Progress Across Rare Skin Disease Pipeline with Two Poster Presentations at the 2026 American Academy of Dermatology Annual Meeting
Finviz2026-03-27 14:33:52
Palvella Therapeutics Announces Scientific Publication in Journal of Vascular Anomalies Highlighting the Infiltrative Growth and Therapeutic Challenges of Microcystic Lymphatic Malformations
Finviz2026-03-30 11:33:46
Palvella Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update
Finviz2026-03-31 11:33:51
Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales
Finviz2026-04-07 11:33:11
Palvella Positioned for Early Market Shift with QTORIN Rapamycin NDA Expected in Second Half of 2026
101 finance2026-04-07 12:31:02
Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
Finviz2026-03-02 12:33:44
Palvella Therapeutics Announces Issuance of European Patent Covering Anhydrous Compositions of Rapamycin
Finviz2026-03-16 11:33:05
Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services
Finviz2026-03-23 11:33:56
Palvella Therapeutics to Host Full Year 2025 Financial Results Conference Call and Provide a Corporate Update on March 31, 2026
Finviz2026-03-24 11:33:39
Palvella Therapeutics Highlights Continued Progress Across Rare Skin Disease Pipeline with Two Poster Presentations at the 2026 American Academy of Dermatology Annual Meeting
Finviz2026-03-27 14:33:52
Palvella Therapeutics Announces Scientific Publication in Journal of Vascular Anomalies Highlighting the Infiltrative Growth and Therapeutic Challenges of Microcystic Lymphatic Malformations
Finviz2026-03-30 11:33:46
Palvella Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update
Finviz2026-03-31 11:33:51
Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales
Finviz2026-04-07 11:33:11
Palvella Positioned for Early Market Shift with QTORIN Rapamycin NDA Expected in Second Half of 2026
101 finance2026-04-07 12:31:02
PVLA stock chart
PVLA stock detailsPVLA stock price change
On the last trading day, PVLA stock closed at 130.20 USD, with a price change of 5.71% for the day.
Trade stock perpsAbout Bitget
The world's first Universal Exchange (UEX), enabling users to trade not only cryptocurrencies, but also stocks, ETFs, forex, gold, and real-world assets (RWA).
Learn more